XXresearch – COPD Treatment

What: A Randomised, Double-blind, Double Dummy, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 3 Doses of Benralizumab (MEDI-563) in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TERRANOVA)

Who: Male & Females 40 to 85 (inclusive) (Former Smokers)

Duration: 56 weeks

Name*
First Last
Phone*
Email*
Have you been diagnosed with COPD?*
Have you recently taken an antibiotic and or a steroid?*
Have you been hospitalized in the past 12 months?*
Do you use tobacco or have you ever been a smoker?*